Grufity logo
Grufity logo
RPTX

RPTX - Repare Therapeutics Inc Stock Price, Fair Value and News

$2.65 
Market Closed as of 28 Jan 2026, 04:00 pm ET

Price Targets

RPTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RPTX Price Action

Last 7 days

1.6%

Last 30 days

2.8%

Last 90 days

33.7%

Trailing 12 Months

114.8%

RPTX RSI Chart

RPTX Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

RPTX Valuation

Market Cap

113.9M

Price/Earnings (Trailing)

-1.58

Price/Sales (Trailing)

16.24

EV/EBITDA

-0.62

Price/Free Cashflow

-1.62

RPTX Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

RPTX Fundamentals

RPTX Revenue

RPTX Earnings

RPTX Profitability

Free Cashflow Yield

-61.58%

RPTX Investor Care

Revenue & Growth

How Repare Therapeutics Inc generates revenue and covers its expenses, based on the latest reported earnings.

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)
Net sales
YearQ1Q2Q3Q4
20259.0M7.3M7.0M-
202412.9M12.3M11.5M10.4M
20238.9M11.9M13.2M13.3M
2022324.0K830.0K2.8M5.6M
2021244.8K249.5K254.3K259.0K
2020---240.0K
Get all data in R, Python etc through our Historical Stock Data APIs(opens in new tab)

About Repare Therapeutics Inc

RPTX
Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing PKMYT1 Inhibitor (RP-6306), which is under Phase ½ clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has icense and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; and Ono Pharmaceutical Co. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in St-Laurent, Canada.
 CEO
 WEBSITEreparerx.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES180

Repare Therapeutics Inc Frequently Asked Questions

RPTX is the stock ticker symbol of Repare Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Repare Therapeutics Inc is 113.91 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

As of Wed Jan 28 2026, RPTX's PE ratio (Price to Earnings) is -1.58 and Price to Sales (PS) ratio is 16.24. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. RPTX PE ratio will change depending on the future growth rate expectations of investors.